Jefferies analyst David Steinberg raised his price target for Valeant Pharmaceuticals to $19 from $18 and keeps a Buy rating on the shares following the company's Q4 results. The company's fiscal 2018 financial guidance was well below consensus due to more than expected loss of exclusivities and increased investment in its core businesses, Steinberg tells investors in a post-earnings research note. While fiscal 2018 will be a down year, management believes growth can reaccelerate in fiscal 2019 and beyond from new product launches, the analyst adds.